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Abstract
The ability to precisely upregulate genes in inflamed brain holds great therapeutic promise. Here we report a novel class of
vectors, genetically modified macrophages that carry reporter and therapeutic genes to neural cells. Systemic
administration of macrophages transfected ex vivo with a plasmid DNA (pDNA) encoding a potent antioxidant enzyme,
catalase, produced month-long expression levels of catalase in the brain resulting in three-fold reductions in inflammation
and complete neuroprotection in mouse models of Parkinson’s disease (PD). This resulted in significant improvements in
motor functions in PD mice. Mechanistic studies revealed that transfected macrophages secreted extracellular vesicles,
exosomes, packed with catalase genetic material, pDNA and mRNA, active catalase, and NF-kb, a transcription factor
involved in the encoded gene expression. Exosomes efficiently transfer their contents to contiguous neurons resulting in de
novo protein synthesis in target cells. Thus, genetically modified macrophages serve as a highly efficient system for
reproduction, packaging, and targeted gene and drug delivery to treat inflammatory and neurodegenerative disorders.
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Introduction
Development of new delivery systems for gene and drug
transport for neurodegenerative disorders, including Parkinson’s
and Alzheimer’s diseases (PD and AD), is greatly needed. The
challenges faced are: limited blood brain barrier (BBB) perme-
ability, inherent peripheral and brain drug toxicities, and low
therapeutic indices. The pathobiology of PD and AD is linked to
microglial activation and subsequent secretion of neurotoxic
factors. These include reactive oxygen and nitrogen species
(ROS and RNS) leading to oxidative stress [1–4], which affects
neuronal, astrocyte, and microglia function by inducing ion
transport and calcium mobilization, and activating apoptotic
programs. Apoptosis and excitotoxicity are principal causes of
mitochondrial-induced neuronal death [5]. Indeed, the mitochon-
drial respiratory chain affects oxidative phosphorylation and is
responsible for ROS production. Such pathways lead to neuronal
demise and underlie the pathobiology of PD and AD [6].
The lack of natural antioxidants (glutathione and superoxide
dismutase) and iron in the substantia nigra (SN) are specifically
associated with the pathobiology of PD [7–9]. Removing ROS
and affecting mitochondria function through targeted delivery of
redox enzymes could attenuate disease progression [10]. There-
fore, efficient brain delivery of redox enzymes, such as catalase and
superoxide dismutase, or their replicative genetic material can
attenuate ROS and improve disease outcomes. Unfortunately,
antioxidants when administered as therapeutic agents fail to alter
the course of PD-associated neurodegeneration [11]. We posit that
such failures may be a result from limited delivery of antioxidants
at disease sites. Taking advantage of the neuroinflamatory process
and the active egress of immunocytes from blood to sites of
inflammation, we developed monocytes/macrophages as drug
carrier systems for inflammatory-mediated diseases [12–18]. The
system rests in the ability of blood borne macrophages to carry
antioxidant proteins across the BBB to affected brain subregions.
To preclude macrophage-mediated enzyme degradation, catalase
was packaged into a block ionomer complex with a cationic block
copolymer, poly(ethyleneimine)-poly(ethylene glycol) producing
nanosized particles, ‘‘nanozymes’’. We demonstrated that such
nanozyme-loaded macrophages systemically administered into
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mice with brain inflammation facilitated nanozyme transport
across the BBB. In addition the cell-carriers provided sustained
and prolonged release of catalase suggesting a depot role for the
enzyme [13]. It was demonstrated that at least a portion of
macrophages loaded with nanozyme migrate from the blood away
into the tissue and the tissue-associated cell-carriers slowly unload
and supply the blood plasma providing sustained levels of catalase
in the plasma over seven days.
Furthermore, macrophages discharged nanozyme to contiguous
cells facilitating decomposition of ROS, reducing neuroinflamma-
tion, and attenuating nigrostriatal degeneration that ultimately
produced potent neuroprotection in PD mice. The transfer of
nanozyme from macrophages to target recipient cells is by a)
partial transient fusion of cellular membranes, b) formation of
macrophage bridging conduits (BCs), filopodia and lamellipodia,
and 3) release of exosomes, extracellular vesicles that contain the
nanozyme [18].
Exosomes are specialized membranous vesicles, that are
secreted by a variety of cells, particularly cells of the immune
system: dendritic cells [19], macrophages [20], B cells [21], and T
cells [22]. Exosomes were initially thought to be a mechanism for
removing unneeded membrane proteins from reticulocytes.
Recent studies have shown that they are specialized in long-
distance intercellular communications facilitating transfer of
proteins [23], and functional mRNAs and microRNAs for
subsequent protein expression in target cells [24,25]. The efficient
cell-to-cell transfer is accomplished by facilitated membrane
interactions and fusion, expression of adhesive proteins and
specific vector ligands (tetraspanins, integrins, CD11b and CD18
receptors) on the surface of exosomes [19,26]. To shuttle their
cargo, exosomes can attach by a range of surface adhesion proteins
and fuse with the cell-target membrane. We demonstrated
previously that incorporation of nanoformulated catalase (‘‘nano-
zyme’’) in exosomes altered its intracellular localization in target
cells of neurovascular unit (neurons, brain microvessel endothelial
cells, and astrocytes) enabling to reach different intracellular
compartments such as ER, cytoplasm, and mitochondria, where
ROS may be efficiently deactivated by catalase [18].
Another approach for targeted cell-mediated delivery system is
using genetically-modified cell-carriers that were transfected with
pDNA encoding a therapeutic protein. In this case, transfected
cells can achieve gene delivery providing a sustained expression of
the therapeutic protein in the inflamed brain. It was reported that
genetically-modified cell-carriers were used for successful gene
therapy of PD and AD. Thus, neurotropic factors, brain-derived
neurotropic factor (BDNF) [27,28], glial cell-line derived neuro-
tropic factor (GDNF), or vascular endothelial growth factor
(VGEF) were delivered by transfected neural stem cells (NSC)
[29–31], or bone marrow-derived macrophages [32] for treatment
of PD-related inflammation and neuronal degeneration. Further-
more, transfected NSC were also used for delivery of neurotrophic
factors in AD mouse models [27,33–36].
Based on our previously developed cell-mediated delivery
system for nanoformulated catalase, the present work utilized
genetically-modified immunocytes for targeted gene and drug
delivery in PD model. In particular, RAW 264.7 macrophages
were transfected with pDNA encoding reporter proteins (GFP, or
luciferase, or tomato protein), or the therapeutic protein (catalase).
The gene and protein transfer from genetically-modified macro-
phages, and their therapeutic effect were evaluated in in vitro and in
vivo PD models. We demonstrated for the first time that
systemically administered transfected macrophages release exo-
somes with incorporated in them DNA, mRNA, transcription
factors molecules, and the encoded protein. This resulted in the
sustained catalase expression and subsequent potent anti-
inflammatory and neuroprotective outcomes in PD models. Two
models of brain inflammation were used, intracranial (i.c.)
injections with lipopolysaccharides (LPS) or 6-hydroxidophamine
(6-OHDA). We demonstrated earlier that LPS intoxications
caused higher levels of neuroinflammation, which was manifested
earlier than in case of 6-OHDA injections (typically 48 hours vs.
21 days following the intoxication, respectively) [15]. Nevertheless,
hallmarks of 6-OHDA-induced neuroinflammation reflected PD-
related process better than LPS-intoxications. We did not use
intraperitoneal (i.p.) MPTP-intoxications that is also a common
model of PD. The i.p. MPTP injections usually cause significant
inflammation in peripheral organs (liver, spleen, and kidneys) that
redirects considerable portion of macrophages from brain to these
peripheral organs. Thus, i.c. intoxications with 6-OHDA and LPS
are the most appropriate PD models for cell-mediated drug
delivery evaluations. Overall, cell-mediated drug delivery is a
promising strategy for targeted transport of therapeutic genes and
drugs, which could provide a missing link for translational gene
therapy of inflammatory and neurodegenerative disorders.
Materials and Methods
Plasmids
The gWIZTM high expression vectors encoding the reporter
genes luciferase (gWIZTMLuc) and green fluorescent protein (GFP)
(gWIZTMGFP) both under control of an optimized human
cytomegalovirus (CMV) promoter followed by intron A from the
CMV immediate-early (IE) gene were used throughout the study
(Gene Therapy Systems, San Diego, CA). The expression vector
encoding tomato protein reporter gene was purchased from
Clonetech Laboratories Inc. (Mountain View, CA). Human
catalase pDNA ORF clone (NM_001752) was provided by
OriGene (Rockville, MD). All plasmids are expanded in DH5a
e.coli and isolated using Qiagen endotoxin-free plasmid Giga-prep
kits (Qiagen, Valencia, CA) according to the protocol.
Reagents
GenePORTER 30000 transfection agent was purchased from
AMS Biotechnology, England). LPS, 6-OHDA, and Triton X-100
were obtained from Sigma-Aldrich (St. Louis, MO, USA). Alexa
Fluor-678-conjugated anti-CD11b was purchased from BD
Biosciences (San Diego, CA). Rabbit polyclonal anti-GFP
antibodies (A6455), secondary chicken anti-rabbit HRP-conjugat-
ed antibodies (A829), and antibodies to human catalase (A16772-
100) were obtained from Abcam (Cambridge, MA). Anti-NeuN
Antibodies were purchased from EMD Millipore, (Billerica, MA).
CD63 and NFkB P65 monoclonal antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). A luminescent
substrate, D-Luciferase, was purchased in Caliper Life Sciences
(Hopkinton, MA). A nucleic acid stain, YOYO-1 iodide (491/
509), was obtained from Invitrogen (Carlsbad, CA).
Cells
A mouse macrophage cell line (RAW 264.7) was purchased
from ATCC (cat # TIB-71), and cultured in Dulbecco’s Modified
Eagle’s Media (DMEM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% FBS. Mouse catecholaminergic Cath.A
neurons were purchased from American Type Culture Collection
(American Type Culture Collection, ATCC, Manassas, VA,
USA), and cultured in RPMI-1640 medium supplemented with
8% normal horse serum (NHS), 4% fetal bovine serum (FBS), and
1% penicillin-streptomycin. Cath.A neurons were differentiated by
Macrophages as Proxy for Gene Transfer
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61852
adding 1 mM of N6,29-O-dibutyryladenosine 39,59-cyclic mono-
phosphate sodium salt (dbcAMP, St. Louis, MO, USA) [37].
Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Nebraska Medical Center
(Permit Number: 05-087-12). All surgery was performed under
sodium pentobarbital anesthesia, and all efforts were made to
minimize suffering. Balb/c male mice (Charles River Laboratories,
USA) eight weeks of age were used in the in vivo IVIS experiments
to reduce fluorescence quenching by colored skin and fur. The
animals were kept five per cage with an air filter cover under light-
(12-hours light/dark cycle) and temperature-controlled (2261uC)
environment. All manipulations with the animals were performed
under a sterilized laminar hood. Food and water were given ad
libitum.
Transfection of Macrophages: Protein Expression and
Release
RAW 264.7 macrophages were incubated with a mixture of
2 mg/ml GFP, or catalase, or luciferase, or tomato protein pDNA
and GenePORTER 3000 for four hours. Following incubation,
the cells were washed with PBS, cultured for various time points
(up to 21 days) in complete media with 20% FBS, and then GFP
expression was accounted by fluorescence activated cell sorting.
Next, the same conditions were used for macrophages transfection
with catalase, or luciferase, or tomato protein pDNA under the
control of CMV promoter.
For measures of the overexpressed protein release, culture
media from transfected macrophages was collected at various time
points, and assessed for amount of fluorescence for GFP-
transfected macrophages (Shimadzu RF5000 fluorescent spectro-
photometer; lex = 488 nm, lem = 501 nm), or catalase enzymatic
activity in case of transfection with catalase pDNA using Amplex
Red assay as described previously [12]. Briefly, media samples
from transfected macrophages were supplemented with Amplex
Red Dye stock solution (10 U/mL HRP, 10 mM Ampex Red) for
30 minute, and ROS content was measured by fluorescence at
lex = 563 nm, lem = 587 nm according to the manufacturer’s
specifications. Amount of the expressed enzyme was normalized
for protein content and expressed in U of catalase per mg of the
protein as means 6 SEM (N = 4). To exclude the possibility that
cell death explains the release of catalase and GFP, percentage of
live macrophages on the fourth day after transfection was
accounted by FACS. For this purpose, transfected cells were
collected, washed, stained with Alexa 488 LIVE/DEAD dye
according to manufacturer’s protocol, and the amount of
accumulated dye was assessed (N = 4). The mean +/2 standard
deviation was less than 10%.
Isolation of Exosomes
RAW 264.7 macrophages grown on 75T flasks (206106 cells/
flask) were transfected with GFP, catalase, or tomato protein
pDNA as described above, washed three times with PBS, and fresh
media was added to the cells. Following 48 hours, cellular media
was collected, filtered through 20 mM filter to eliminate cellular
debris, and exosomes were isolated using Exoquick Exosome
Precipitation Solution (System Biosciences, Mountain View, CA).
The obtained exosomal fraction was re-suspended in PBS (500 ml,
1 mg/ml total protein), and evaluated for protein and genetic
material content. In separate experiments, exosomes isolated from
tomato protein-transfected macrophages were added to Cath.A
neurons and dynamics of pDNA accumulation and the encoded
protein expression in target cells were visualized by confocal
microscopy.
Atomic Force Microscopy (AFM)
Exosomes from catalase-transfected or non-transfected macro-
phages were isolated, and the obtained exosomal fraction at total
protein 1 mg/ml was diluted 100 times in PBS. A drop of the
sample was placed on positively charged mica treated with 1-(3-
aminopropyl) silatrane (APS) [38] for 2 minutes, washed with
deionized water, and dried under an argon flow. The AFM
imaging was operated as described [17]. Image processing and the
cross-section analysis were performed using Femtoscan (Advanced
Technologies Center, Moscow, Russia). The height of the particles
and their diameters measured at half-maximal height were
obtained from the cross-section analysis. The volume was
approximated by a hemisphere using the equation [39]. A
standard t-test was performed for the size comparison of exosomes
released from catalase-transfected and non-transfected macro-
phages.
Western Blot Analysis
Western blot technique was applied to examine protein content
of exosomes secreted from GFP- or empty vector-transfected
RAW 264.7 macrophages, in particular, the presence of GFP and
transcription factor, NF-kB. Protein concentrations were deter-
mined using NanoDrop 2000 (Nano Drop Products, Wilmington,
DE). Primary rabbit polyclonal antibodies to GFAP were used at
1:1,000 dilution. Secondary chicken anti-rabbit HRP-conjugated
antibodies were used in 1:4,000 dilution. NF-kB P65 monoclonal
antibodies were used at 1:50,000 dilution. Specific protein bands
were visualized by Immobilon Western Chemiluminescent HRP
Substrate kit (Millipore, Billerica, MA), and quantitated by
densitometry (Bio-Rad Laboratories, Hercules, CA) [12]. To
correct for loading differences in exosomal fractions, the levels of
proteins were normalized to CD63 that is constitutively expressed
in exosomes.
PCR and RT-PCR Analyses
cDNA synthesis. Exosomes were diluted to 1 ug/mL of
protein, lysed, treated with DNase and reverse transcribed using
SuperScriptTM III CellsDirect cDNA Synthesis System according
to manufacturer’s protocol. For DNA samples exosomes were
lysed and treated with RNase to prepare them for PCR.
Polymerase Chain Reaction. PCR was performed using
GFP primers (the forward sequence was 5-TCTGGGACA-
CAAATTGGAATACAACT-3 and reverse sequence was
CGGGTCTTGAAGTTCACTTTGATTC-3) using PlatinumH
Taq DNA Polymerase (Invitrogen). Final concentrations of
reagents were as follows: 16PCR buffer, 0.2 mM dNTP mixture,
1.5 mM MgCl2 0.2 mM forward primer, 0.2 mM reverse primer
and 2 U DNA polymererase in distilled water. 4% cDNA or
RNase treated lysate (see above) was added. The reaction mixture
was incubated in a thermocycler for 30 seconds at 94uC, then 35
cycles of denaturing (94u for 15–30 sec), annealing (59uC for
30 sec), and extention (72uC for 1 min) were performed. DNA was
subjected to agarose gel electrophoresis (1% agarose at 60 V for
90 min) and subsequent ethidium bromide staining (.5 ug/mL
Ethidium bromide in 16 TAE), and imaged with Bio-Rad Gel
DocTM instrument.
Real Time PCR. 40 mL DEPC treated water was used to
dilute cDNA and DNA obtained as described above. 3 mL of this
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dilution was analyzed by real-time PCR. The real-time PCR
reaction was carried out using TaqMan Gene Expression Master
Mix and Expression Assays (Mouse GAPDH (The forward primer
was 5-TCACTGGCATGGCCTTCC-3, the reverse sequence
was 5-GGCGGCACGTCAGATCC-3, and the TAMRA probe
sequence was 5-TTCCTACCCCCAATGTGTCCGTCG-3 ) and
custom eGFP primers (ABI Assay ID:AIWR2DN)) using manu-
facturer protocols on an ABI 7700 Sequence Detector System
(Applied Biosystems). Results were analyzed using the DDCt
method.
Production of a Lentiviral Vector (LV)
Lentiviral vectors encoding a fusion between GFP and firefly
luciferase (FLuc) were created by PCR amplifying the cDNA
sequences for GFP and FLuc from pEGFP (Clontech) and
pcDNA-Luciferase (Addgene) with restriction enzyme sequences
that were engineered into the primers. To create the final
constructs, GFP was digested with BamHI/EcoV and FLuc was
digested with EcoV/XhoI. The digested fragments were ligated into
the BamHI/XhoI digested pTK402 LV transfer vector (a kind gift
from Dr. Tal Kafri, The University of North Carolina at Chapel
Hill). LV-GFPFLuc viral vectors were packaged in 293T by
transient transfection using the psPAX2 and pMD2.G (Addgene)
packaging plasmids and following previously described protocols
[40].
Confocal Microscopy Studies
GFP expression in RAW 264.7 macrophages was visualized by
a confocal fluorescence microscopic system ACAS-570 (Meridian
Instruments, Okimos, MI) with argon ion laser (excitation
wavelength, 488 nm) and corresponding filter set. Digital images
were obtained using the CCD camera (Photometrics) and Adobe
Photoshop software. To visualize catalase expression, transfected
with catalase pDNA macrophages were fixed with 4% parafor-
maldehyde (PFA) for 15 min, treated with 0.4% Triton for 4 min,
and then stained with primary mouse antibodies to human
catalase, and Alexa 488-conjugated secondary goat anti mouse
antibodies (1:200 Dilution, Invitrogen, Carlsbad, CA, USA). Non-
specific interactions were blocked with 3% BSA for 30 min prior
the staining with antibodies.
To examine accumulation of exosomes secreted from macro-
phages in neuronal cells, RAW 264.7 macrophages (206106 cells/
flask) were cultured for three days in DMEM supplemented with
10% FBS, and then concomitant media was collected, exosomes
were isolated with Exoquick Exosome Kit according to manufac-
turer’s protocol, and labeled with lipophilic fluorescent dye, 3,39-
dilinoleyl-oxacarbocyanine perchlorate (DIO) [18]. Then, Cath.A
neurons grown on chamber slides (16105 cells/chamber) [41]
were supplemented with the DIO-labeled exosomes (1 mg of total
protein/100 ml) and incubated for another 24 hours. Neurons
were stained with Anti-NeuN Antibodies (blue) prior to the
imaging.
To visualize genetic material and the encoded protein transfer
from exosomes to neurons, pDNA encoded tomato protein was
labeled with a fluorescent dye YOYO-1 (green) prior to
macrophages transfection. Then, RAW 264.7 macrophages were
transfected with YOYO-1 labeled pDNA encoded tomato protein,
and cultured in DMEM media. To visualize genetic material
transfer from exosomes to neurons, the media from the tomato
protein-transfected macrophages was collected, the exosomes
(0.5 mg/ml) were isolated and added to Cath.A neurons grown
on chamber slides (16105 cells/chamber). Confocal images of the
neurons accumulating YOYO-labeled DNA (green) and express-
ing tomato protein (red) were taken at different times with
corresponding laser and filter sets. Neurons were fixed and stained
with Anti-NeuN Antibodies (blue) prior to the imaging.
To study macrophage-mediated gene transfer in vivo, mice with
brain inflammation induced were i.v. injected with GFP-transfect-
ed macrophages (56106 cells/mouse in 100 ml PBS) on day four
after transfection. In the control experiment, mice with brain
inflammation were i.v. injected with LV-GFPFLuc virus (26104
particles/100 ml/mouse). One and five days later, animals were
sacrificed and perfused as described [15], main organs (brain,
liver, spleen, and lymph nodes) were removed, washed, post-fixed
in 10% phosphate-buffered paraformaldehyde, and evaluated by
confocal microscopy. Healthy mice (without brain inflammation)
were used as controls.
Fluorescence Activated Cell Sorting (FACS)
Number of GFP-transfected macrophages and the expression
levels (in relative fluorescent units (RFU) were assessed by FACS.
Typically, RAW 264.7 macrophages transfected with GFP
pDNA/GenePORTER 3000 reagent were cultured in DMEM
complete media for various times, then the cells were detached,
collected and the amount of the expressed GFP was accounted by
FACS.
To evaluate kinetics of GFP transfer from the transfected
macrophages to Cath.A neurons, GFP-transfected RAW 264.7
macrophages (16106 cells/sample) were cultured for four days in
DMEM media supplemented with 20% FBS, and then added to
Cath.A neurons (16106 cells/sample, 1:1 ratio). The co-cultured
cell mixture was collected at different time points and the amount
of GFP in macrophages and neurons was assessed by FACS. To
distinguish between the cell types, macrophages were labeled with
Alexa 678-conjugated antibodies to CD 11b prior to the
assessment. The expression levels GFP levels were plotted vs. time
of co-culture.
Induction of Brain Inflammation in Mice
For 6-OHDA and LPS intoxications, mice were stereotactically
injected into substantia nigra pars compacta (SNpc) with 6-OHDA
solution (10 mg 6-OHDA in 0.9% NaCL with 0.02% ascorbic
acid), or LPS solution (10 mg LPS in 0.9% NaCl with 0.02%
ascorbic acid), respectively, flow rate of 0.1 mL/min into the
striatum (AP: +0.5; L: 22.0 and DV: 23.0 mm) [15]. Three or
four weeks after 6-OHDA intoxication, or 24 hours after LPS
intoxication, the animals were injected via the intrajugular vein
(i.v.) with GFP2, or luciferase-, or catalase-transfected macro-
phages (56106 cells/mouse in 100 ml PBS).
Bioimaging and Infrared Spectroscopy (IVIS)
To reduce fluorescence quenching by fur, Balb/c mice were
shaved prior to the imaging. Luciferase-transfected macrophages
were i.v. injected on day 3 after transfection to 6-OHDA-
intoxicated mice (56106 cells/mouse in 100 ml PBS) on day 21
after the intoxication. A solution of bioluminescent substrate, D-
Luciferin, was injected intraperitoneally (i.p.) (100 ml/mouse)
before the cell adoptive transfer. Healthy animals without brain
inflammation were used in the control group (N = 4). In another
neuroinflammation model, LPS-intoxicated mice were i.v. injected
with catalase-transfected macrophages on day four after transfec-
tion. Ten minutes before imaging, each animal received an i.p.
injection of XenoLight RediJect Inflammation probe, a chemilu-
minescent reagent for monitoring inflammation (Caliper, Hop-
kinton, MA). This probe is offered in a ready-to-use format and
can be conveniently applied to study myeloperoxidase (MPO)
activity of activated phagocytes. The animals were imaged at
various time points (15 minutes–40 days) post-treatment as
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described [13]. The chemoluminescent signal was quantified by
living imageH 2.50 software and presented as radiance ratio of
treated animal vs. 24 hours after LPS injection.
Immunohistochemical and Stereological Analyses
6-OHDA-intoxicated mice were i.v. injected with PBS, or
catalase-transfected macrophages, or macrophages transfected
with empty vector (56106 cells/mouse/100 ml) 48 hours after
the intoxication. Healthy non-intoxicated animals i.c. injected with
PBS instead of 6-OHDA were used in two control groups that
were i.v. injected with PBS or empty-transfected macrophages
(N = 7) 48 hours after PBS i.c. injections. Four weeks later, animals
were sacrificed, perfused; brains were removed, washed, post-
fixed, and immunohistochemical analysis was performed in 30 mm
thick consecutive coronal brain sections [13]. For detection of
microglia activation, tissue sections were incubated with primary
monoclonal rat anti-mouse anti-CD11b antibodies (1:500 dilu-
tion), and secondary biotinylated goat anti-rat antibodies (Vector
Laboratories, Burlingame, CA, 1:200 dilution). For the assessment
of neuroprotection effect, a tyrosine hydroxylase (TH) staining was
used to quantitate numbers of dopaminergic neurons (DA) [42].
The total number of TH-positive DA neurons and CD11b-positive
microglia cells were counted by using the optical fractionator
module in StereoInvestigator software (MicroBrightField, Inc.,
Williston, VT) [13].
Behavioral Tests
For the traditional constant speed rotarod test, mice were
trained and tested as previously described [43] with slight
modifications. 6-OHDA-intoxicated mice (N = 10) were i.v. inject-
ed with PBS, or catalase-transfected macrophages, or empty-
transfected (with GFP-encoded pDNA) macrophages 48 hours
after intoxication and the latency to fall from the rotarod was
determined at three speeds (4, 5, and 7 rpm) on day 28 after
intoxication. Healthy mice with PBS i.c. injections were used as a
control [44]. For apomorphine test, the four groups of mice (i.c.
PBS/i.v. PBS; i.c. 6-OHDA/i.v. PBS, i.c. 6-OHDA/i.v. catalase-
transfected macrophages, and i.c. 6-OHDA/i.v. empty-transfected
macrophages) were injected with apomorphine (0.05 mg/kg, s.c.)
on day 28 after intoxication, and rotations were scored every
10 min for 90 min [45].
Statistical Analysis
For the all experiments, data are presented as the mean 6
SEM. Tests for significant differences between the groups in in vitro
experiments investigating transfection of macrophages, as well as
in in vivo evaluations of therapeutic effects of different drug
formulations were performed using a one-way ANOVA with
multiple comparisons (Fisher’s pairwise comparisons) using
GraphPad Prism 5.0 (GraphPad software, San Diego, CA,
USA). A standard t-test was performed when only two groups
were compared (for example, for size evaluation of exosomes
released from transfected and non-transfected macrophages). A
minimum p value of 0.05 was chosen as the significance level for all
tests.
Results
Transfection of the Cell-carriers with Reporter and
Therapeutic Proteins
Efficient transfection of cell-carriers is crucial for their use as
drug and gene delivery vehicles. Therefore, at first, the optimal
conditions for macrophage transfection (exposure time, DNA and
transfection reagent ratios) were determined. Statistically signifi-
cant increases in the expression of reporter green fluorescent
protein (GFP), and catalase were found (Fig. 1). The best results
were obtained, when macrophages were transfected using
GenePORTER 3000 transfection agent incubated with 2 mg/ml
pDNA encoded GFP, or catalase for four hours, and cultured in
complete media with 20% FBS. Up to 40% of cells expressed GFP
with maximal gene expression by day 4 was detected by FACS
(Fig. 1 A), and confocal microscopy (Fig. 1 C). A sustained
protein expression and prolonged release into the media for at
least 21 days was detected by GFP fluorescence, or catalase
enzyme activity (Fig. 1 B), and confirmed by confocal microscopy
in catalase-transfected macrophages (Fig. 1 D). Important, the
pick of the GFP fluorescence in macrophages at day 4 was
followed by the sharp decreases in the expression levels and
number of the transfected cells indicating relatively transient
transfection of macrophages with GenePORTER 3000. Notewor-
thy, 95.7% of transfected macrophages releasing the encoded
protein were alive on day four as confirmed by FACS. This
excludes the possibility that the release of catalase and GFP into
concomitant media could be a result of cell death.
Biodistribution of Systemically Administered
Macrophages in Mice and Transfection of the Inflamed
Brain Tissues
It was reported that macrophages can carry and release their
‘‘payload’’ to distal sites of inflammation in various disease
conditions, as reported [13,18,32,46]. Thus, we demonstrated
previously that injected intravenously fluorescently-labeled bone-
marrow derived macrophages can cross the BBB and deliver
nanoparticles with therapeutically active enzyme to the inflamed
brain tissues [13]. Here, we use two in vivo models, characterized
by ongoing brain inflammation caused by 6-OHDA or LPS
intracranial injections into substantia nigra pars compacta (SNpc). First,
to examine whether genetically-modified macrophages can reach
the brain and deliver their payload, image visualization and
infrared spectroscopy studies (IVIS) were conducted 6-OHDA
intoxicated mice. Since luminescence is less quenched by bones
and tissues than fluorescence, the macrophages were first
transfected ex vivo with luciferase pDNA, cultured in complete
media for 3 days, and then i.v. injected to the mice (56106 cells/
100 ml) with or without brain inflammation. In this animal model,
the inflammation reaches maximum around the day 21 after
intoxication, therefore, this time point was also used as the day of
transfected macrophages administration. The luminescent IVIS
images of dorsal planes of the injected animals revealed striking
differences in luciferase levels in mice with brain inflammation
(Fig. 2 A) compared to healthy PBS-injected animals (Fig. 2 B).
Thus, significant luminescence with maximum levels by days 3 to
5 after adoptive cell transfer was detected in the brain of 6-
OHDA-intoxicated mice. In contrast, low, if any, luminescence
was detected in PBS-treated animals injected with luciferase-
transfected macrophages. No luminescence was detected in
another control group of 6-OHDA-intoxicated animals with
systemically administered empty vector-transfected macrophages
(data not shown).
Furthermore, as we reported previously, macrophages that were
labeled by ALEXA 780 fluorescent dye and systemically injected
to 6-OHDA intoxicated mice were not detectable in the brain area
after day 18 following administration [15]. In contrast, the
obtained IVIS images (Fig. 2 A) demonstrated prolonged (over a
month after adoptive transfer) luciferase expression in the inflamed
brain. We speculate that in addition to transfected macrophages,
luminescence may originate from the transfected brain tissues.
Notably, both dorsal (Fig. 2 A) and ventral (Fig. S1) images of
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mice with brain inflammation revealed no luciferase expression in
peripheral organs, liver, kidney, or spleen suggesting active
targeting of genetically-modified macrophages specifically to the
sites of inflammation.
IVIS imaging of live animals does not allow distinguishing
between expressed protein in the blood stream or brain parenchy-
ma. To eliminate this factor, tissue sections of brain and other
organs of interest were prepared from mice with neuroinflammation
(LPS i.c. injections) that were injected with GFP-transfected
macrophages (56106 cells/100 ml/mouse) (Fig. 2 C) one and five
days following macrophages transfer. The confocal images revealed
significant GFP levels by day 1 post transfer in the lesioned brain
hemisphere, spleen, lymph node, and low, if any, fluorescence in
liver. No GFP expression was found in control (non-injected)
hemisphere of the intoxicated animals. At day 5, in addition to GFP-
expressing macrophages, significant fluorescence throughout the
whole brain slides was detected suggesting that genetically-modified
macrophages transfected brain tissues with inflammation. Healthy
mice (without brain inflammation) yielded no GFP expression
within the whole brain and much lesser levels in liver, spleen, and
lymph nodes (Fig. S2). Together these data provide initial evidence
that transfected macrophages achieved targeted drug delivery to
inflammation sites increasing expression of the desired protein in the
brain, but not in other peripheral tissues known to be sites amenable
for macrophage migration.
Catalase-transfected Macrophages Reduce
Neuroinflammation in PD Mouse Models
Linkages between neuroinflammation and nigrostriatal degen-
eration have been reported [47]. Thus, transfection of brain tissues
to express a redox enzyme, catalase, to attenuate inflammation
could serve to protect dopaminergic neurons in disease [3,4]. The
ability of catalase-transfected macrophages to reduce brain
inflammation was demonstrated first, by IVIS studies in BALB/
c mice stereotactically injected with LPS into SNpc. The extent of
inflammation as a chemiluminescence signal within the brain
produced by Xenolight RediJect was quantified and presented as a
radiance ratio of treated animals vs. LPS-injected mice at 24 hours
after the LPS injection (Fig. 3 A). LPS intoxication induced 2.3-
fold increase (SEM 6 0.3, N = 4) in brain inflammation levels in
LPS-injected mice compared to the day first after intoxication
(blue curve). In contrast, systemically administered catalase-
Figure 1. Transfection of macrophages with GFP or catalase pDNA and prolonged release of the encoded protein. Raw 264.7
macrophages were incubated with 2 mg/ml GFP (A, C) or catalase (B, D) pDNA and 300 ml/ml Gene PORTER 3000 transfection agent for 4 hours,
washed, and cultured in complete media for various times. Levels of the encoded protein and percentage of transfected macrophages were assessed
by FACS (A), and the expressed protein (green) was visualized by confocal microscopy on day 4 (C), and day 21 (D). Up to 40% of cells expressed GFP
(A) with the maximum at day 4 (A, C) and sustained expression for at least 21 days (D). For the release studies, macrophages grown on 24-well plates
were transfected with: GFP pDNA (B, black squares) or catalase pDNA (B, white squares), then cells were washed, cultured for different times, and
amount of the expressed protein was assessed by fluorescence (GFP) or catalytic activity (catalase). In consistence with the transfection levels,
maximum of the encoded protein was detected in the culture media at day 4 with sustained levels up to three weeks. Levels of fluorescence and
enzymatic activity in non-transfected macrophages are shown by arrow on corresponding axes and dashed lines. Statistical significance of GFP
expression levels in macrophages, and GFP or catalase released from macrophages compared to untreated cell levels is shown by asterisk (*p,0.05;
**p,0.005) was calculated by one-way ANOVA. Errors are mean 6 SEM, N = 4. The bar: 20 mm.
doi:10.1371/journal.pone.0061852.g001
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transfected macrophages cased statistically significant decreases in
neuroinflammation in LPS-intoxicated mice (2.1 times, SEM 6
0.03 at day 7, N = 4), which was sustained for over a month after
LPS intoxication (red curve). The representative IVIS images
indicate complete abrogation of brain inflammation at day 30 by
the single i.v. injection of catalase-transfected macrophages (Fig. 3
A).
Next, potent anti-inflammatory and neuroprotective effects of
catalase-transfected macrophages were demonstrated in the 6-
OHDA-intoxicated mice (Fig. 3 B, C). I.c. injections of 6-OHDA
up-regulated expression of CD11b by microglia within the SNpc as
exhibited a more amoeboid morphology in 6-OHDA-treated mice
compared to ramified microglia in PBS-treated mice (Fig. 3 B,
Table 1). In contrast, treatment of 6-OHDA-intoxicated mice
with catalase-transfected macrophages resulted in the decreased
levels of CD11b and 65% less activated microglia cells compared
with 6-OHDA-intoxicated control animals (Fig. 3 B, Table 1).
Finally, systemic administration of catalase-transfected macro-
phages completely prevented neurodegeneration in 6-OHDA
intoxicated mice (Fig. 3 C, Table 1). The numbers of TH+
neurons in SNpc of 6-OHDA animals treated with catalase-
transfected macrophages were significantly (p,0.05) greater than
those 6-OHDA intoxicated, and then PBS-injected animals.
Noteworthy, the number of survived TH+ neurons in the
Figure 2. Transfection of brain tissues by genetically-modified macrophages in murine models of PD. Balb/C mice were i.c. injected into
substantia nigra pars compacta, SNpc with 6-OHDA (A), or with PBS (B). Twenty one days after injections, mice were i.v. injected with luciferase-
transfected macrophages. IVIS representative images from N = 4 mice per group demonstrate prolonged expression of luciferase in the brain (A),
which peaked at days 3–5 after adoptive cell transfer. Stable luciferase expression levels were attained over a month, suggesting that along with the
delivered luciferase, recorded luminescence may originate from the transfected brain tissues. In contrast, low, if any, luminescence was detected in
the healthy animals (B). I: whole body images, II: images of mouse head for corresponding time. C: Sections of midbrain (both hemispheres), spleen,
lymph nodes and liver of Balb/C mice i.c. injected with LPS into SNpc, and then i.v. injected GFP-transfected macrophages (24 hour following
intoxication). Brain sections obtained after 24 hours after transfer (left column) show GFP-expressing macrophages in the ipsilateral hemisphere,
spleen, lymph node. No fluorescence was detected in the liver, as well as in the contralateral brain hemisphere. Notably, substantial fluorescence
throughout the whole brain was demonstrated five days after macrophages administration (right column) suggesting that genetically-modified
macrophages transfected ipsilateral brain tissues with inflammation. The bar: 20 mm.
doi:10.1371/journal.pone.0061852.g002
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ipsilateral side of 6-OHDA-intoxicated mice treated with catalase-
transfected macrophages appears to be even greater (p,0.05) than
those in the PBS-injected of control animals, which probably
developed slight brain inflammation due to PBS i.c. injections.
This signifies that catalase-transfected macrophages can efficiently
reduce 6-OHDA-induced nigrostriatal inflammation and abolish
subsequent neurodegeneration. No effect on microglia activation
was found in control mice that were intoxicated with 6-OHDA,
and then treated with empty vector-transfected macrophages.
Nevertheless, these empty vector-transfected macrophages have
subtle, but statistically significant neuroprotective effect in mice
with i.c. PBS injections (Fig. 3 B, C and Table 1). We
hypothesized that a particular subset of alternatively activated
macrophages used in these studies (i.e. differentiated in presence of
MCSF) has a regeneration effect as was also reported in [48].
Finally, behavioral tests demonstrated statistically significant
improvements in motor functions upon treatment with catalase-
transfected macrophages (Fig. 4). Specifically, the loss of
dopaminergic input due to the lesion of the left nigro-striatial
pathway resulted in number of full-body contralateral rotations
induced by a dopaminergic agent, apomorphine. In contrast,
systemic administration of catalase-transfected macrophages to 6-
OHDA intoxicated mice considerably (p,0.05) reduced number
of these rotations on the seventh week following the intoxication in
apomorphine test (Fig. 4 A). Furthermore, the motor functions
were preserved by systemic administration of catalase-transfected
macrophages in 6-OHDA intoxicated animals at the levels similar
to those of control non-intoxicated mice, as demonstrated in
rotarod test (Fig. 4 B). Noteworthy, no effect on motor functions
was recorded upon administration of empty-transfected macro-
phages.
Cargo of Exosomes Secreted from Transfected
Macrophages
The significance of these findings is further underscored by the
ability of macrophages to shed small vesicles (exosomes and
microvesicles) [26] which can contain RNA, proteins and even
Figure 3. Anti-inflammatory and neuroprotective effects of catalase-transfected macrophages in PD murine models. A: LPS-induced
encephalitis in BALB/C mice were injected i.v. with catalase-transfected macrophages (red curve), or PBS (blue curve). IVIS images over 40 days were
taken ten minutes after intraperitoneal (i.p.) injection of a XenoLight RediJect probe for inflammation. The chemiluminescent signal was quantified
and presented as radiance ratios of treated animal after 24 hours after LPS injection and at various times thereafter. Genetically-modified
macrophages caused prolonged decreases of neuroinflammation in LPS-intoxicated mice. IVIS representative images at day 30 are shown. (B) and (C):
BALB/c mice were i.c. injected with 6-OHDA. Forty eight hours later animals were i.v. injected with catalase-transfected macrophages, and 21 days
later they were sacrificed, and mid-brain slides were stained for expression of B: CD11b, a marker for activated microglia or C: TH, a marker for
dopaminergic neurons. Whereas 6-OHDA treatment caused significant microglia activation and neuronal loss, administration of catalase-transfected
macrophages dramatically decreased oxidative stress, and increased neuronal survival. Administration of empty-vector transfected macrophages did
not affect microglia activation, or number of dopaminergic neurons in in mice with brain inflammation. Statistical significance (shown by asterisk:
p,0.05) was assessed by a standard t-test compared to mice with i.c. LPS injections followed by i.v. PBS injections (healthy controls). Values are
means 6 SEM (N = 4).
doi:10.1371/journal.pone.0061852.g003
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pre-loaded in such cells nanoparticles [18]. Here we evaluated
whether transfected macrophages release these extracellular
organelles with encapsulated pDNA, mRNA and protein products.
From culture supernatants, we enriched for exosomes and
microvesicles and assessed this fraction for the presence of the
transgene DNA and RNA by PCR and RT-PCR analyses
(Fig. 5 A, B). The results showed presence of both DNA and
RNA of the encoded protein (here GFP) in exosomes released
from transfected macrophages (Fig. 5 A). Important, the levels of
the genetic material were about four orders of magnitude greater
compared to the exosomes secreted from non-transfected macro-
phages (Fig. 5 B, group 1), as well as from the cells transfected
with an empty vector (Fig. 5 B, group 2). Western blot analysis
indicated that exosomes released from transfected macrophages
contained 6.1 times greater levels of the expressed transgene
protein (GFP) than those obtained from cells transfected with
empty vector (Fig. 5 C). Finally, exosomes contained considerable
amount of the transcription factor, NF-kB, which is particularly
involved in the GFP expression under CMV promoter (Fig. 5 D).
This indicates that exosomes represent a highly efficient packaging
system that can be used for the delivery of proteins and genetic
material to target cells.
AFM images show round morphology of isolated exosomes
from non-transfected macrophages presenting an average diam-
eter of 48.160.03 nm (Fig. 5 E). The donut-like shape is
indicative of hollow vesicles with a central depression that appears
Table 1. Effect of catalase-transfected macrophages on inflammation and neurodegeneration in mice with PD modela.
Treatment CD11b+ (cells/mm
2) Total N of neuronsb 6103
PBS 6-OHDA PBS 6-OHDA
PBS 10.161.2 90.0611 (**)c 6.961.9 2.560.5 (**)
Catalase-transfected macrophages n/a 31.267.0 (*) n/a 9.761.4 (*, #)
Empty-transfected macrophages 9.861.0 89.0611.1 8.262.1 3.260.7
aBALB/c mice were i.c. injected with 6-OHDA. Forty eight hours later, the animals were i.v. injected with various macrophage-based formulations or PBS. Control group
was i.c. injected with PBS, and then 48 hours later i.v. injected with PBS.
bTotal number of neurons was calculated in ipsilateral hemisphere.
cStatistical significance is shown by asterisk: p,0.05 (*), and p,0.005 (**) compared to mice with i.c. PBS injections followed by i.v. PBS injections (healthy controls); or
p,0.05 (#),compared to mice with i.c. 6-OHDA injections followed by i.v. PBS injections (PD controls); was performed by a1+standard t-test. Errors are mean 6 SEM,
N = 7.
doi:10.1371/journal.pone.0061852.t001
Figure 4. Therapeutic effect of catalase-transfected macrophages on motor functions in a PD mouse model. BALB/c mice were i.c.
injected with 6-OHDA. Forty eight hours later, the animals were i.v. injected with catalase-transfected macrophages (bars with diagonal pattern) or
PBS (black bars), or empty-transfected macrophages (white bars). Control group was i.c. injected with PBS, and then 48 hours later i.v. injected with
PBS (grey bars). Apomorphine (A) and rotaroid (B) tests demonstrated statistically significant improvements in motor functions upon treatment with
catalase-transfected macrophages. Number of rotations (A) was significantly decreased in 6-OHDA-intoxicated mice treated with catalase-transfected
macrophages compared to non-treated PD mice. No rotations were detected in control PBS-injected mice in apomorphine test. Time spent on the
rotarod (B) in 6-OHDA intoxicated mice treated with catalase-transfected macrophages was the same as in healthy non-intoxicated control mice on
the seventh week after the intoxication. In contrast, significant decreases were observed in 6-OHDA-intoxicated mice injected with PBS. No effect on
motor functions was recorded in 6-OHDA-intoxicated mice treated with empty-transfected macrophages. Statistical significance was calculated using
one-way ANOVA test. Values are means 6 SEM (N = 10), and p,0.05 compared with aPBS, and b6-OHDA.
doi:10.1371/journal.pone.0061852.g004
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upon drying in vacuum. Notably, exosomes from catalase-
transfected macrophages were significantly larger
(66.560.05 nm, p,0.001) compared to exosomes from non-
transfected cells with a spherical shape sans central depression that
may be due to packaging of the encoded protein and its genetic
material (Fig. 5 F).
Accumulation of Exosomes from Transfected
Macrophages in Neurons
To study the exosomal transfer, exosomes isolated from
macrophages concomitant media were labeled with lipophilic
dye, DIO, and then Cath.A neurons were supplemented with
these pre-labeled exosomes for 24 hours. Confocal images
demonstrated substantial accumulation of DIO-labeled exosomes
(green) in target cells (Fig. 6 A). Next, to visualize the gene transfer
from exosomes to neurons, pDNA encoded tomato protein was
labeled with a nucleoside stain, YOYO-1, and then RAW 264.7
macrophages were transfected with this pre-labeled pDNA.
Confocal images of the transfected macrophages cultured in the
complete media for three days revealed the nuclear accumulation
of YOYO-1-labeled pDNA (green) and the expression of the
encoded tomato protein (red) in cytoplasm of the genetically-
modified macrophages (Fig. 6 B). Finally, media from the
transfected macrophages was collected in day 3, and the isolated
exosomal fraction was added to Cath.a neurons (Fig. 6 C) to
visualize genetic material transfer and the expression of the
encoded protein. Indeed, the neurons exposed to the macrophage-
derived exosomes first accumulated the YOYO-1-labeled pDNA
entrapped in these exosomes on day 1, and then expressed
encoded red tomato protein on day 3 (Fig. 6 C). The
quantification of the green and red fluorescence in confocal
images revealed a relatively constant amount of pDNA and time
dependent increased expression of tomato protein (Fig. 6 C,
graph). This suggests that exosomes released from transfected-
macrophages can carry transgene and subsequently transfect
neurons signifying the possible use of macrophages as proxy for
gene transfer into the acceptor cells.
Kinetics of Gene Transfer from Genetically-modified
Macrophages to Target Neurons
The kinetics of the gene transfer from macrophages to neurons
was validated by FACS. Here RAW 264.7 macrophages were
transfected with GFP pDNA, cultured in the complete media for
three days, and then added to Cath.A neurons at 1:1 of
Figure 5. Exosomes secreted from GFP-transfected macrophages contain GFP DNA, RNA, the transcription factor, and expressed
protein. Exosomes from GFP-transfected cells were collected over two days and evaluated for (A): GFP DNA (1) and RNA (2) by PCR analysis.
Exosomes secreted from macrophages transfected with empty vector were used as a control (3). (B): Levels of GFP DNA and RNA in exosomes from
GFP-transfected macrophages were compared to those from empty vector-transfected macrophages (1), or non-transfected cells (2) by Real-Time
PCR analysis. C: expression levels of GFP (30K) in exosomes from GFP-transfected cells (1) or empty vector-transfected macrophages (2) were
examined by western blot and compared to the levels of CD63 (53K). Exosomes released from GFP-transfected macrophages contained four orders of
magnitude more of GFP DNA and RNA compared to non-transfected macrophages or those transfected with empty vector (A, B); and 6.1 times
greater levels of the expressed protein, GFP (C). Exosomes contain substantially higher levels of NF-kb, a transcription factor that involved in GFP
pDNA expression, compared to macrophages as demonstrated by western blot (D). AFM images of exosomes revealed differences between: (E) small
donut-shaped (empty) exosomes released from non-transfected macrophages, and (F) large spherical (likely filled with the expressed proteins and
genetic material) exosomes from catalase-transfected macrophages. The bar: 200 nm.
doi:10.1371/journal.pone.0061852.g005
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macrophage-neuron ratio. To distinguish between the donor
(macrophages) and receiver (neurons) cells, macrophages were pre-
labeled with antibodies to CD11b before the cell sorting. About
99.8% of macrophages were labeled (Fig. 7, Day 0). At 48 hours
of the co-culture, GFP appears to be expressed exclusively in
macrophages revealed as a CD11b+ population of cells (Fig. 7,
Day 5). Over the time, GFP expression increases in neurons along
with the appearance of CD11b marker in them (Fig. 7, Day 7)
that ultimately yields one indistinguishable cell population (Fig. 7,
Day 12). Taking into account that Cath.A neurons efficiently
accumulate exosomes from transfected macrophages (Fig. 6 A),
we suggest that neurons co-cultured with transfected macrophages
Figure 6. Accumulation of exosomes secreted from macrophages in Cath.A neurons and genetic material transfer. A: Cath.A neurons
grown on slides were fixed and stained with Anti-NeuN Antibodies (blue, left picture); exosomes were isolated from Raw 264.7 macrophages media,
stained with lipophilic fluorescent dye, DIO (green), and added to Cath.A neurons for 24 hours (right picture). B: Raw 264.7 macrophages were
transfected with fluorescently-labeled with YOYO-1 tomato protein pDNA (green), and then cultured in complete media. Confocal images of
transfected macrophages on day 3 show incorporation of pDNA (green) in the nucleus and expression of tomato protein (red) in the cytoplasm.
C: Media from macrophages transfected as described above with tomato protein pDNA (labeled with YOYO-1) was collected over 24 hours, and
isolated exosomes were added to Cath.A neurons for various times. Then, the neurons were fixed and stained with Anti-NeuN Antibodies (blue).
Confocal images of neurons incubated with exosomal fraction demonstrated relatively constant amount of YOYO-1-labeled pDNA (green), and
increasing in time expression levels of tomato protein (red) confirmed by the quantification of green and red fluorescence on confocal images
(graph). Co-localization of YOYO-1-labeled genetic material and expressed tomato protein in neurons is manifested by yellow staining. Statistical
significance of tomato protein expression levels (shown by asterisk: p,0.05) was assessed by a standard t-test compared to day one after
transfection. The bar: 20 mm.
doi:10.1371/journal.pone.0061852.g006
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acquired some of the CD11b-containig membranes of exosomes
along with GFP genetic material and the expressed protein.
Noteworthy, the GFP expression levels in macrophages alone
sharply declined after day 4 after transfection, as shown in
Fig. 1 A. In contrast, the co-culture of macrophages and neurons
displays a delayed GFP expression profile, with the maximal
expression shifted to day 8–12 (Fig. 7, graph). We hypothesized
that at the earlier times GFP gene expression is mostly associated
with the macrophages, while at later times, expression by neurons
increases and macrophage expression fades. This reinforces the
Figure 7. Transfection of Cath.A neurons by GFP-transfected macrophages. RAW 264.7 macrophages were transfected with GFP pDNA,
cultured in complete media for three days, and then added to Cath.A neurons. To distinguish between the cell types, macrophages were stained with
CD11b Ab (Alexa 647). GFP levels in neurons were assessed by FACS as mean fluorescence 6 SEM (N = 4). A: The representative FACS plots
demonstrating GFP transfer into Cath.A neurons; B: Quantification of GFP levels in macrophages alone (black diamonds), and in co-culture of neurons
and macrophages (white squares). GFP expression levels in neurons co-cultured with transfected macrophages increased over 5–12 days. At the same
time, protein expression in macrophages at days 5–12 was already diminished, suggesting that along with GFP, its genetic material (pDNA and RNA)
was transferred from transfected macrophages into neurons, where the encoded protein (GFP) was synthesized de novo. Statistical significance
shown by asterisk (p,0.05) was calculated by a one-way ANOVA. The bar: 10 mm.
doi:10.1371/journal.pone.0061852.g007
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notion that genetic material as well as protein products from
transfected macrophages can be transferred to acceptor cells,
where additional protein is synthesized de novo. Important, 97.6%
of transfected macrophages and neurons in co-cultured mixture
were alive on day 12 as confirmed by FACS.
Overall, these data support the importance of macrophage-
based gene and catalase carriage for PD therapies. Indeed,
mechanism of this cell-mediated drug delivery is not fully
understood and warrants further studies.
Discussion
PD is the fastest growing neurologic disorder in the developed
world. Although much of the pathology remains unrealized, it is
known to be associated with brain inflammation, microglia
activation and neurotoxic activities including ROS that facilitate
neuronal damage and death [1–4]. Thus, the need to deliver
neuroprotectants, in particular, redox enzymes involved in anti-
inflammatory neuroprotection, such as catalase and superoxide
dismutase (SOD), to control neuroinflammation in the affected
brain cannot be overstated. Several studies have shown that
reduction of the oxidative stress-related damage, including ROS-
scavenging, are attractive strategies if successfully delivered to the
sites of inflammation within the brain [10,49]. Unfortunately,
many promising approaches fail to show benefits in humans, in
part due to severe limitations imparted by the BBB, and the lack of
delivery of therapeutic polypeptides to the brain [50,51]. Utilizing
the common approach to oxidative stress, we developed a novel
cell-based gene and drug delivery system of antioxidants that
features tissue specificity, and efficient penetration of the BBB.
We report here developing macrophages that were stably
transfected with catalase pDNA to produce a therapeutically active
enzyme that can efficiently reduce ROS and benefit neuronal
survival during upregulated oxidative stress similar to that
associated with PD. To accomplish this goal, first, genetically-
modified macrophages should be able to reach the brain
inflammatory sites in substantial quantities; therefore their
migratory activity should not be compromised by the transfection.
We demonstrated here that systemically administered macrophag-
es transfected with luciferase pDNA reached the inflammatory site,
delivering the encoded protein to the brain in PD mouse model.
Interesting, maximum luciferase expression in the brain was
detected on days 3 to 5 after macrophage transfer and was
prolonged over a month with upregulated protein levels. Based on
our previous IVIS data [13] indicating that i.v. injected
fluorescently-labeled macrophages reach the inflamed brain sites
maximum at day 5 with further their complete elimination by day
18, we hypothesized that luminescence recorded three weeks after
i.v. administration of luciferase-transfected macrophages may
originate not only from the transfected cell-carriers, but also from
the secondary transfected brain tissues. Noteworthy, little, if any,
luminescence was recorded in peripheral organs in mice with
brain inflammation, or in the brain of healthy controls, suggesting
targeted gene and drug delivery by macrophages to the inflamed
brain.
Next, to eliminate possibility recording the expressed protein in
the blood vessels, slides of the main organs of mice that were
injected with GFP-transfected macrophages and then perfused to
wash out the blood content were examined by fluorescence
confocal microscopy. The confocal images of the brain slides
confirmed macrophage-mediated delivery of the overexpressed
protein to the SNpc as early as 24 hours after systemic adminis-
tration. Notably, brain tissues from the ipsilateral hemisphere
demonstrate significant fluorescence throughout the SNpc area 5
days after macrophages administration. This reinforces our
hypothesis that genetically-modified macrophages secondarily
transfected brain tissues.
The major question, whether catalase transfected macrophages
can produce a neuroprotective effect in PD mice was divided into
two parts: i) decrease of neuroinflammation, and ii) increase of
dopaminergic neuron survival. The level of inflammation was
evaluated using a marker for activated microglia, antibodies to
CD11b. In mice, the neurotoxin 6-OHDA reproduces most of the
biochemical and pathological hallmarks of PD, including specific
degeneration of dopaminergic neurons that originate in the SNpc
and enervate the striatum. The results presented in this work
clearly demonstrated that, catalase-transfected macrophages show
profound anti-inflammatory and neuroprotective effects in murine
models of neuroinflammation and PD. Thus, systemic adminis-
tration of catalase-transfected macrophages resulted in a substan-
tial and prolonged attenuation of neuroinflammation (over 40
days) in mice with neuroinflammation. Furthermore, catalase-
transfected macrophages dramatically decreased inflammation,
and increased neuronal survival in 6-OHDA-intoxicated mice.
Therapeutic efficacy of the catalase-transfected macrophages was
confirmed by 2.9-fold reductions in microgliosis as measured by
CD11b expression, and 3.9-fold increase in tyrosine hydroxylase
(TH)-expressing dopaminergic (DA) neurons as measured by TH,
a marker for dopaminergic neurons, compared to 6-OHDA-
intoxicated mace treated with PBS. Noteworthy, the number of
survived DA neurons of mice after i.c. 6-OHDA intoxication
followed by transfected macrophages systemic administration was
even greater than those in control healthy mice i.c. injected with
PBS. The potent neuroprotective effect by catalase-transfected
macrophages was further manifested in significant improvements
in motor functions in the 6-OHDA mouse model.
The most remarkable finding of this study is the fact that
genetically-modified macrophages released the expressed protein
and its genetic material (DNA and RNA) in exosomes, specialized
membranous vesicles, that may facilitate transfer of their cargo to
contiguous target neurons, similarly to the previously reported
macrophages pre-loaded with drug-incorporated catalase nano-
particles [18]. Exosomes and microvesicles by themselves have
attracted recently a significant attention as naturally occurring
nanoparticles that may provide a noninvasive and novel thera-
peutic approach for efficient delivery of drugs across impermeable
barriers, in particular the BBB [52–55]. This approach allows
using individualized and biocompatible therapeutic drug delivery
vehicles that can pass unrecognized by the patient’s immune
system (because they are, in fact, a part of immunocytes) and
deliver the expressed therapeutic load to the disease site. However,
two main challenges when using exosomes remain: a) the
efficiency of drug loading into the exosomes, and b) targeting
the exosomes to a particular cell type or organ. These challenges
may be resolved by using transfected cell-carriers for targeted gene
and drug delivery.
Thus, we report here that DNA and RNA of the encoded
protein were detected in exosomes secreted from genetically-
modified macrophages by PCR and RT-PCR analyses. The data
indicate four orders of magnitude increases in both DNA and
RNA levels of the encoded protein in exosomes released from
transfected macrophages compared to those from non-modified
cells. Next, the up-regulated amount of NF-kb, a transcription
factor involved in pDNA expression, was detected in exosomes by
western blot. This may further facilitate transfection and high
expression levels of the encoded protein in target cells of a
neurovascular unit (neurons, astrocytes, and brain microvessel
endothelial cells). In fact, confocal microphotographs confirmed
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transfer of fluorescently-labeled DNA to neurons from exosomes
released by transfected macrophages in vitro. Notably, expression of
the encoded protein in the neurons was increased over time, while
DNA levels remain constant. This indeed is crucial for therapeutic
efficacy of an antioxidant that may have greater therapeutic effect
when transferred into neurons. Furthermore, additional indica-
tions of the genetic transfer from cell-carriers to target cells were
revealed in differences between the kinetics of the encoded protein
expression in transfected macrophages cultured alone, or in co-
culture with neuronal cells. The maximum protein expression in
macrophages alone occurs on day 4 after the transfection followed
by sharp decreases. In contrast, neighboring neurons pick up the
expression of the protein by 8–12 days after macrophage
transfection, suggesting that de novo synthesis of protein occurs
mostly in the neurons at later times.
In this study, we clearly demonstrate the ability of macrophages
to deliver genetic material to the CNS suggesting this approach
may represent a new and novel alterative for gene therapy. To
date, the majority of gene delivery systems have relied on viral
vectors, of which adenovirus (Ad), adeno-associated (AAV), virus
and retrovirus/lentivirus (LV) are the most commonly used
[56,57]. In the ideal setting, viral vectors are capable of achieving
robust transgene expression. However, their application has been
limited by high levels of immune system activation, minimal
transduction efficiency, and reliance on direct intracranial
administration [58]. When delivered systemically, studies have
shown that less than 1 in 100 copies of systemically administered
LV are detectable in the brain [59]. This is supported by our
findings which showed expression of GFP was undetectable in the
brain following intravenous infusion of LV vectors (Fig. S3).
Although certain types of AAV are more efficient at transducting
the brain [60], wide variation among serotypes is observed
following systemic administration [58]. In contrast, we observed
macrophages are capable of effectively and efficiently delivering
transgenes into the brain. As such, macrophage-based gene
therapy may offer several potential advantages over traditional
viral vector therapy. First, generation of macrophage-based
delivery systems may increase the ease of generation. Macro-
phage-based systems are not reliant on cloning of transgenes into
viral backbones or by viral packaging constraints that limit the size
of transgenes. Secondly, viral vectors rely on specific receptors for
entry and delivery of their single DNA or RNA-based transgene
that can result in low or absent tranduction. With the ability to
deliver DNA, as wells as exosomes carrying protein and mRNA
simultaneously, macrophage-based delivery of multiple payloads
in a receptor-independent manner may overcome the low
transduction efficiency observed with certain viral vectors.
Additionally, the simultaneous delivery of DNA, RNA, and
protein by macrophages may enhance the efficacy of therapeutic
proteins compare to traditional viral vectors. Lastly, one of the
greatest limitations of Ad or LV vectors is robust activation of the
host immune system [57]. One could envision the transplantation
of autologous macrophages carrying therapeutic transgenes. Using
a patient’s own cells should minimize or eliminate activation of the
host immune response by the drug delivery vehicle. Despite the
potential advantages of macrophage delivery, there are still
numerous limitations that need to be addressed. Although we
did observed gene expression for greater than 3 weeks, we
Figure 8. A pictorial scheme for cell-based gene and drug delivery. Three possible ways of therapeutic effects of catalase-transfected
macrophages in PD mouse model: Pathway I : macrophages transfected with catalase encoding pDNA cross the BBB and release catalase and its
genetic material in SNpc; Pathway II : catalase and its genetic material are released from transfected macrophages in exosomes to the blood stream
and bypass the BBB independently of the cell-carriers; Pathway III : gene and drug-incorporating exosomes released in the periphegral organs (liver,
spleen, etc.) or in the blood are taken by residential macrophages, monocytes, T-cells, or dendritic cells suppressing peripheral leukocyte activation
that may result in decrease of inflammation in the brain.
doi:10.1371/journal.pone.0061852.g008
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anticipate transgenes delivered by macrophages will not integrate
into the target cell genome and therefore will only be transiently
expressed. Thus, expression will not persist as long as genes
delivered by AAV or LV that are capable of genome integration.
Furthermore, it is unclear how the levels of gene expression by
macrophage-based delivery compare to viral-based gene delivery
and how this may affect therapeutic efficacy. Extensive future
investigation will be required to clearly define the precise
advantages and disadvantages of macrophage-based gene therapy
compared to established viral vector technology; however the
results of this study clearly demonstrate the potential of this new
approach.
Overall, these studies indicate that genetically-modified macro-
phages serve as a new type of vector for gene transfer. They
implement more than only inert carrier functions by being mini-
factories for multiplication, packaging, and targeted gene and drug
delivery to the inflammation site. Taking into account that
exosomes from macrophages may efficiently adhere to neurons
due to the presence of various adhesive glycoproteins [19,61,62],
fuse to their membranes and deliver their content [18], we
hypothesized that genetic material was shuttled into neurons by
this mechanism resulting in fundamental effect on neuronal
survival during oxidative stress in murine models of PD.
We cannot discern at this point the main mechanism of the
neuroprotective effects produced by systemically administered
catalase-transfected macrophages. First, these cells may cross the
BBB and deliver catalase and its genetic material to the inflamed
brain (Fig. 8, Pathway I). Second, catalase transfected macro-
phages may release at least a portion of exosomes with catalase
and catalase genetic material in the blood stream and then these
extracellular vesicles reaches CNS independently of cell-carriers
(Fig. 8, Pathway II). Another possibility is that exosomes
released from macrophages in the peripheral organs (liver, spleen,
etc.) or blood stream are taken by host circulating monocytes,
residential macrophages, T cells, etc., which deliver exosomes with
their cargo to SNpc by the same route as transfected macrophages
shown in these studies (Fig. 8, Pathway III). Indeed, further
mechanistic studies are necessary to understand the role of the cell-
carriers and their exosomes in the encoded protein and gene
transfer from macrophages to neurons. We anticipate that this
system can be used for active targeted gene and drug delivery and
has a potential for clinical translation.
Supporting Information
Figure S1 Biodistribution of expressed Luciferase in
mice with brain inflammation by IVIS. Balb/C mice were
i.c. injected with 6-OHDA (0.5 mg/kg) into the substantia nigra
pars compacta, SNpc. In parallel, RAW 264.7 macrophages were
transfected with luciferase pDNA formulated with GenePorter
3000 transfection agent, cultured in complete media for three
days, and then administered through i.v. (56106 cells/100 ml) into
the mice with brain inflammation following 21 days after 6-
OHDA administration (A). Healthy mice were used as controls (B).
Representative images from N = 4 mice per group (ventral planes)
taken at various time points revealed no luminescence in the brain
in both mice with brain inflammation as well as healthy animals.
No luminescence was detected in peritoneal area, liver, or spleen
in mice with brain inflammation.
(DOCX)
Figure S2 Tracking of GFP-transfected Macrophages in
healthy mice. RAW 264.7 macrophages were transfected with
GFP pDNA formulated with GenePorter 3000 transfection agent,
cultured in complete media for 3 days, and then administered
through intrajugular vein (56106 cells/100 ml/mouse) into the
mice with brain inflammation following 24 hours after LPS
administration. 24 hours later mice were sacrificed and perfused
with PBS and 4% PFA. Brain, spleen, and lymph nodes were
frozen; tissue specimens were sectioned with a cryostate (10 mm
thick) and examined by confocal microscopy (606magnification).
Representative images from N = 4 animals demonstrate low, but
detectable amounts of BMM in the liver (B), spleen (C), and lymph
node (D). No macrophages were found in the healthy brain (A).
The bar: 20 mm.
(DOCX)
Figure S3 Tracking of LV-GFPFLuc virus in mice with
brain inflammation. BALB/c mice were i.c. injected with LPS
into SN as described in Materials and Methods. Twenty four hours
later, the animals were i.v. injected with LV-GFPFLuc virus
(26104 particles/100 ml/mouse). One day (A) and 5 days (B) later
mice were sacrificed, and perfused with PBS and 4% PFA. Brains
were frozen, sectioned with a cryostate (10 mm thick), and
examined by confocal microscopy (606magnification). Represen-
tative images from N = 4 animals detected no fluorescence in the
brain indicating that LV-GFPFLuc virus particles were not able to
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